2021

Professional development Vacancies
2021
Regarding amendments to the instructions for medical use of medicinal products containing ceftriaxone (ceftriaxone)

Having considered and analyzed the available evidence (EudraVigilance, literature), and taking into account the plausible biological mechanism of action, the degree of causal relationship between the development of hepatotoxicity…

Read more
Health Canada has published information on a new safety issue: dopamine agonist withdrawal syndrome

This information is published for the purpose of awareness and to encourage reporting of similar adverse reactions. Key messages Withdrawal syndrome of agonists…

Read more
Health Canada and the US Food and Drug Administration (FDA) have published new safety information on COVID-19 vaccines: the risk of myocarditis and pericarditis

Key messages Cases of myocarditis and pericarditis after immunization with COVID-19 vaccines have been registered in Canada and other countries. These messages…

Read more
The Ministry of Health of Canada (Health Canada) has published new information on the AstraZeneca COVID-19 Vaccine and COVISHIELD: risk of capillary leak syndrome

This safety issue has already been highlighted by the European Medicines Agency (EMA); in particular, a communication to healthcare professionals has been published (https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-vaxzevria-previously-covid-19-vaccine-astrazeneca_en-1.pdf)…

Read more
Health Canada has published new information on the safety of the use of systemic corticosteroids

Systemic corticosteroids (including dexamethasone) and pheochromocytoma crisis when administered to patients with established, suspected, or unrecognized pheochromocytoma. Key messages…

Read more
Regarding amendments to the instructions for medical use of COVID-19 vaccine (ChAdOx1-S) [recombinant]) – Vaxzevria/COVID-19 AstraZeneca

Following the results of the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC), recommendations were issued on updating the instructions for medical use, and…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing phenytoin

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing…

Read more
Signal from the VigiBase database of the Uppsala Monitoring Centre: COVID-19 vaccines and trigeminal neuralgia (neuralgia of the trigeminal nerve)

(signal under investigation – no final conclusion) A preliminary safety signal was detected in the VigiBase database. A disproportionate series was recorded, comprising…

Read more
Regarding amendments to the instructions for medical use of COVID-19 vaccine (ChAdOx1-S) (recombinant) – Vaxzevria/COVID-19 AstraZeneca

Additional analysis of data obtained from the EudraVigilance database, with review of individual cases (conclusions and recommendations are based on the results of a search from…

Read more
VigiBase database signal (Uppsala Monitoring Centre): remdesivir and pancreatotoxicity

(signal at the stage of further monitoring) Remdesivir is a new antiviral agent that received emergency approval during the COVID-19 pandemic year…

Read more